Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

HAEMATOLOGICA

FERRATA STORTI FOUNDATION

1. Deutsche Krebshilfe [1095969, 111424]
2. Deutsche Forschungsgemeinschaft (DFG) [Ju 295/13-1]
3. Janssen Pharmaceuticals
4. MSD Pharma